Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Dynamic cultivation of human mesenchymal stem/stromal cells for the production of extracellular vesicles in a 3D bioreactor system.

Almeria C., Weiss R., Keck M., Weber V., Kasper C., Egger D.

Laboratory Study on Face & Skin, published in Biotechnol Lett (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Biotechnol Lett (2024)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
38349512
PMCID
PMC10902030
DOI
10.1007/s10529-024-03465-4
Citations
11

Abstract (original English)

Purpose 3D cell culture and hypoxia have been demonstrated to increase the therapeutic effects of mesenchymal stem/stromal cells (MSCs)-derived extracellular vesicles (EVs). In this study, a process for the production of MSC-EVs in a novel 3D bioreactor system under normoxic and hypoxic conditions was established and the resulting EVs were characterized. Methods Human adipose-derived MSCs were seeded and cultured on a 3D membrane in the VITVO® bioreactor system for 7 days. Afterwards, MSC-EVs were isolated and characterized via fluorescence nanoparticle tracking analysis, flow cytometry with staining against annexin V (Anx5) as a marker for EVs exposing phosphatidylserine, as well as CD73 and CD90 as MSC surface markers. Results Cultivation of MSC in the VITVO® bioreactor system demonstrated a higher concentration of MSC-EVs from the 3D bioreactor (9.1 × 10 9 ± 1.5 × 10 9 and 9.7 × 10 9 ± 3.1 × 10 9 particles/mL) compared to static 2D culture (4.2 × 10 9 ± 7.5 × 10 8 and 3.9 × 10 9 ± 3.0 × 10 8 particles/mL) under normoxic and hypoxic conditions, respectively. Also, the particle-to-protein ratio as a measure for the purity of EVs increased from 3.3 × 10 7 ± 1.1 × 10 7 particles/µg protein in 2D to 1.6 × 10 8 ± 8.3 × 10 6 particles/µg protein in 3D. Total MSC-EVs as well as CD73 - CD90 + MSC-EVs were elevated in 2D normoxic conditions. The EV concentration and size did not diffe

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansExtracellular VesiclesMesenchymal Stem CellsBioreactors

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research